|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | General Electric Co. (NYSE:GE), a diversified manufacturer with substantial interests in medical imaging equipment and life sciences. |
|---|---|
| Transferring Party | Whatman Plc, a UK-based maker of filtration products and technologies for research, life sciences and medical technology applications. |
| Sector | Diagnostics |
| Date | February 4, 2008 |
| Analysis Expands GE's $1.3b life science unit, formed with its 04 purchase of Amersham. GE provides tools for manufacturing biopharmaceuticals such as vaccines, cell therapies and antibodies. Whatman's filtration and sample preparation technologies adds new methods to help researchers with the role genes and proteins play in disease. Deal Value -- $717m on sales of $230m (3.2x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |